A cadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial. The negative ...

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company had reported earnings ...

Nuplazid's Background and Current Indication Acadia Pharmaceuticals (NASDAQ: ACAD) is a biotech with one currently approved product, Nuplazid. Nuplazid is approved for Parkinson's Disease psychosis.

Q2 2025 Management View Catherine E. Owen Adams, CEO, stated that "Our second quarter performance reinforces the momentum we're building across all facets of our business from commercial strength to ...

The underperformance can be attributed to the company’s flagship drug Nuplazid, which is currently used to treat hallucinations associated with Parkinson’s disease psychosis, and which saw a ...

Nuplazid is protected through a composition of matter patent that runs to 2021, as well as a use patent in PD to 2026. Investors have raised some concerns about safety, EU-market access and sales.

Nuplazid’s current black box warning cautions that there is “increased mortality in elderly patients with dementia-related psychosis.” Nuplazid is only approved to treat Parkinson’s ...

Now, in the wake of the FDA’s September conclusion that no changes were needed and that Nuplazid’s current label adequately describes its risks, the group is again arguing that Nuplazid was ...

Doctors and other experts tell CNN they worried that a new drug, Nuplazid, aimed at treating Parkinson’s disease patients with hallucinations was approved too quickly. Now hundreds of reports of ...

Acadia Pharmaceuticals Inc. has received U.S. Food and Drug Administration approval for Nuplazid, which the FDA said is the first drug it has approved to treat psychosis associated with Parkinson ...

Nuplazid could offer an important new therapy for the hallucinations, illusions, and delusions experienced by many people with Parkinson's disease.